CN111773239A - Application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries - Google Patents
Application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries Download PDFInfo
- Publication number
- CN111773239A CN111773239A CN202010759735.8A CN202010759735A CN111773239A CN 111773239 A CN111773239 A CN 111773239A CN 202010759735 A CN202010759735 A CN 202010759735A CN 111773239 A CN111773239 A CN 111773239A
- Authority
- CN
- China
- Prior art keywords
- glucan
- beta
- parts
- water
- agrobacterium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920002498 Beta-glucan Polymers 0.000 title claims abstract description 149
- 239000003814 drug Substances 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title claims abstract description 27
- 239000000126 substance Substances 0.000 title claims abstract description 19
- 208000028990 Skin injury Diseases 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title claims abstract description 16
- 230000001737 promoting effect Effects 0.000 claims abstract description 21
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 17
- 230000029663 wound healing Effects 0.000 claims abstract description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 55
- 229910001868 water Inorganic materials 0.000 claims description 54
- 239000000243 solution Substances 0.000 claims description 45
- 241000589158 Agrobacterium Species 0.000 claims description 32
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 32
- FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 32
- 238000000855 fermentation Methods 0.000 claims description 30
- 230000004151 fermentation Effects 0.000 claims description 30
- 239000002244 precipitate Substances 0.000 claims description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 24
- 239000000047 product Substances 0.000 claims description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 20
- 239000011259 mixed solution Substances 0.000 claims description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 17
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 16
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 16
- 229930006000 Sucrose Natural products 0.000 claims description 16
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 16
- 239000001110 calcium chloride Substances 0.000 claims description 16
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 16
- 235000011148 calcium chloride Nutrition 0.000 claims description 16
- 239000011790 ferrous sulphate Substances 0.000 claims description 16
- 235000003891 ferrous sulphate Nutrition 0.000 claims description 16
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 claims description 16
- 229910000359 iron(II) sulfate Inorganic materials 0.000 claims description 16
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 16
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 16
- 229940099596 manganese sulfate Drugs 0.000 claims description 16
- 239000011702 manganese sulphate Substances 0.000 claims description 16
- 235000007079 manganese sulphate Nutrition 0.000 claims description 16
- SQQMAOCOWKFBNP-UHFFFAOYSA-L manganese(II) sulfate Chemical compound [Mn+2].[O-]S([O-])(=O)=O SQQMAOCOWKFBNP-UHFFFAOYSA-L 0.000 claims description 16
- 229910000403 monosodium phosphate Inorganic materials 0.000 claims description 16
- 235000019799 monosodium phosphate Nutrition 0.000 claims description 16
- 239000004323 potassium nitrate Substances 0.000 claims description 16
- 235000010333 potassium nitrate Nutrition 0.000 claims description 16
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 claims description 16
- 229960004793 sucrose Drugs 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 15
- 239000000706 filtrate Substances 0.000 claims description 15
- 239000001963 growth medium Substances 0.000 claims description 14
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 238000004659 sterilization and disinfection Methods 0.000 claims description 14
- 239000005720 sucrose Substances 0.000 claims description 12
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 11
- 238000003756 stirring Methods 0.000 claims description 11
- 238000001914 filtration Methods 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 235000002639 sodium chloride Nutrition 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000000725 suspension Substances 0.000 claims description 10
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 8
- 239000001888 Peptone Substances 0.000 claims description 7
- 108010080698 Peptones Proteins 0.000 claims description 7
- 235000019319 peptone Nutrition 0.000 claims description 7
- 238000001816 cooling Methods 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 5
- 238000010438 heat treatment Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 230000000717 retained effect Effects 0.000 claims description 5
- 206010072170 Skin wound Diseases 0.000 claims description 3
- 238000009423 ventilation Methods 0.000 claims description 3
- 229940124599 anti-inflammatory drug Drugs 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 238000002474 experimental method Methods 0.000 abstract description 45
- 206010061218 Inflammation Diseases 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 21
- 230000004054 inflammatory process Effects 0.000 abstract description 21
- 238000011161 development Methods 0.000 abstract description 4
- 230000018109 developmental process Effects 0.000 abstract description 4
- 230000002500 effect on skin Effects 0.000 abstract description 3
- 241000252212 Danio rerio Species 0.000 description 61
- 230000003110 anti-inflammatory effect Effects 0.000 description 17
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 15
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 210000003491 skin Anatomy 0.000 description 12
- 206010052428 Wound Diseases 0.000 description 11
- 238000011156 evaluation Methods 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000251468 Actinopterygii Species 0.000 description 10
- 229920001503 Glucan Polymers 0.000 description 9
- 210000000440 neutrophil Anatomy 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 7
- 230000008929 regeneration Effects 0.000 description 7
- 238000011069 regeneration method Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 238000004090 dissolution Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 230000009261 transgenic effect Effects 0.000 description 6
- 235000013305 food Nutrition 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 4
- 229920001491 Lentinan Polymers 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 229910000365 copper sulfate Inorganic materials 0.000 description 4
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 4
- 239000002537 cosmetic Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 229940115286 lentinan Drugs 0.000 description 4
- 241001098657 Pterois Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 238000000540 analysis of variance Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 230000004720 fertilization Effects 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 210000003714 granulocyte Anatomy 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- 230000013011 mating Effects 0.000 description 3
- 235000013622 meat product Nutrition 0.000 description 3
- 230000003448 neutrophilic effect Effects 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 238000003825 pressing Methods 0.000 description 3
- 238000001223 reverse osmosis Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 101100227322 Caenorhabditis elegans fli-1 gene Proteins 0.000 description 2
- 241000252233 Cyprinus carpio Species 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 101100281205 Mus musculus Fli1 gene Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000005273 aeration Methods 0.000 description 2
- 238000003975 animal breeding Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000010191 image analysis Methods 0.000 description 2
- 230000000091 immunopotentiator Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 235000004213 low-fat Nutrition 0.000 description 2
- 239000008268 mayonnaise Substances 0.000 description 2
- 235000010746 mayonnaise Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000008354 sodium chloride injection Substances 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- 102100028292 Aladin Human genes 0.000 description 1
- 101710065039 Aladin Proteins 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 102000006311 Cyclin D1 Human genes 0.000 description 1
- 108010058546 Cyclin D1 Proteins 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100039977 Regulator of chromosome condensation Human genes 0.000 description 1
- 101710150974 Regulator of chromosome condensation Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 208000024248 Vascular System injury Diseases 0.000 description 1
- 208000012339 Vascular injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 210000003555 cloaca Anatomy 0.000 description 1
- JZCCFEFSEZPSOG-UHFFFAOYSA-L copper(II) sulfate pentahydrate Chemical compound O.O.O.O.O.[Cu+2].[O-]S([O-])(=O)=O JZCCFEFSEZPSOG-UHFFFAOYSA-L 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 235000011850 desserts Nutrition 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 210000003200 peritoneal cavity Anatomy 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 238000009372 pisciculture Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 210000000434 stratum corneum Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 229940099456 transforming growth factor beta 1 Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 239000012224 working solution Substances 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/04—Polysaccharides, i.e. compounds containing more than five saccharide radicals attached to each other by glycosidic bonds
- C12P19/08—Dextran
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/85—Products or compounds obtained by fermentation, e.g. yoghurt, beer, wine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Wood Science & Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Birds (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses application of beta-1, 3-glucan in preparing a medicament for repairing skin injury and a daily chemical product, aims to introduce the beta-1, 3-glucan into treatment for repairing skin injury, discloses new application of the beta-1, 3-glucan, and discloses application of the beta-1, 3-glucan in preparing the medicament for repairing skin injury and the daily chemical product; experiments prove that the beta-1, 3-glucan has obvious effects of resisting inflammation, promoting tissue regeneration and promoting wound healing, can show that the beta-1, 3-glucan has a repairing effect on skin, and the beta-1, 3-glucan can be applied to preparation of medicines and daily chemical products for repairing skin injury, thereby laying a certain foundation for development of similar medicines and daily chemical products.
Description
Technical Field
The invention relates to the technical field of medicines, in particular to application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries.
Background
Beta-glucan is a macromolecular polysaccharide widely existing in cell walls of microorganisms, plants and seaweeds, a main chain structure is connected by beta-1, 3-glycosidic bonds beta and/or beta-1, 4 glycosidic bonds, and usually contains branched chains connected by beta-1, 6 bonds in different proportions, and main cell walls exist in the form of cell structural components. The glucan containing the beta-1, 3-glycosidic bond has stronger induction and activation effects on a foreign host defense system. In the 40 s of the 20 th century, Piller and Ecker, et al found that an immunostimulating active was present in yeast cells, and until the 60 s of the 20 th century, this active was not confirmed to be β -glucan.
In the prior art, beta-glucan is mainly used in the following three aspects:
1) use in the food industry
Beta-glucan has high viscosity, water retention property, emulsion stability and other properties, and is often used as a thickener, a water retention agent, a binder and an emulsion stabilizer in food industry to be applied to foods such as seasonings, desserts and the like. Because the beta-1, 3-glucan is difficult to digest in human digestive organs and can be used as a non-calorie food additive to provide a fat-like mouthfeel, researches show that the beta-glucan is used for replacing fat in meat products, so that the low-fat meat products not only can provide smooth and rich mouthfeel, but also can improve the textures such as brittleness, hardness, adhesiveness, chewiness and the like of the low-fat meat products and the total acceptability; the beta-glucan is used as a fat substitute and an emulsion stabilizer to be applied to the mayonnaise, so that the emulsion stability of the mayonnaise is effectively maintained, and the storage period of the product is prolonged. In addition, the beta-glucan is non-caloric, can strengthen the effect of the cellulose on preventing lipid absorption, promote cholesterol elimination and increase intestinal peristalsis, can be used as dietary fiber in food to play a role, and is a high-quality health food additive.
2) Use in cosmetics
The rapid development and wide application of modern science and technology bring a brand-new development opportunity to the cosmetic industry, and cosmetics are developed from basic skin care products aiming at cleaning and moistening skin to functional cosmetics aiming at delaying senility and beautifying skin color. Due to the unique biological functions and physicochemical properties of beta-glucan such as oxidation resistance and water absorption, the beta-glucan can have multiple functions of moisturizing, delaying senescence, beautifying skin and the like. It has been shown that water-soluble β -glucan reduces the sensitivity of the skin to radiation when exposed to the UVA region, acts to prevent oxidation of squalene in sebum, and, because of its film-forming properties, also exerts its secondary skin action, helping to provide many biochemical activities to skin cells, such as increasing the moisture retention of the skin and reducing the damage of surfactants to the skin, and can increase the rate of stratum corneum turnover and improve the tightness of the skin.
3) Application in animal breeding and feed industry
Beta-glucan is a good natural immunopotentiator, can improve the nonspecific immunity of organisms, develops and uses the immunopotentiator to improve the immune effect of vaccines, is an important way for improving the health condition of animals, and is quite widely applied to animal breeding and feed industries. Research shows that the specific and non-specific immune functions of the carp can be obviously improved by injecting soluble beta-glucan into the peritoneal cavity of the carp. The beta-glucan is used as an antibiotic substitute to be added into daily food of pigs, chickens and other livestock and poultry, so that the humoral immunity and cellular immunity functions of the livestock and poultry can be obviously improved, the growth of the livestock and poultry is promoted, and the feed value is improved.
However, in order to make β -glucan have a wider application space and value, researchers have been working on β -glucan.
Disclosure of Invention
The invention aims to provide application of beta-1, 3-glucan in preparation of a medicine for repairing skin injury and a daily chemical product. The technical effects that can be produced by the preferred technical scheme in the technical schemes provided by the invention are described in detail in the following.
The invention discloses that the beta-1, 3-glucan has the effect of repairing skin for the first time and can be used for treating skin injury.
The invention particularly discloses application of beta-1, 3-glucan in preparation of a medicine for repairing skin injury and a daily chemical product.
The invention discloses application of beta-1, 3-glucan in preparation of anti-inflammatory drugs for skin and daily chemical products.
The invention discloses application of beta-1, 3-glucan in preparation of a medicament and a daily chemical product for promoting skin tissue regeneration.
The invention discloses application of beta-1, 3-glucan in preparation of medicines and daily chemical products for promoting skin wound healing.
Further, the medicine is an oral medicine or an external medicine; the dosage form of the oral medicine is tablets, capsules or granules; the topical medicine is in the form of powder, lotion, spirit, tincture, ointment, cream, oil, hard preparation or film preparation.
Further, the beta-1, 3-glucan can be used alone or in the form of a pharmaceutical composition comprising a therapeutically effective amount of beta-1, 3-glucan.
Further, the preparation of the beta-1, 3-glucan comprises the following components in parts by weight: 15-25 parts of sodium dihydrogen phosphate, 35-45 parts of potassium nitrate, 3-5 parts of magnesium sulfate, 0.1-0.2 part of calcium chloride, 0.2-0.3 part of ferrous sulfate, 0.04-0.08 part of manganese sulfate, 35-45 parts of rapeseed oil and 620 parts of cane sugar 580-doped materials; water 169900 and 17100 shares;
the preparation also comprises an agrobacterium ZX09 seed solution, and the volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 95-105.
Further, when the beta-1, 3-glucan is prepared, the weight parts of the components are respectively as follows: 18-22 parts of sodium dihydrogen phosphate, 38-42 parts of potassium nitrate, 3.5-4.5 parts of magnesium sulfate, 0.12-0.18 part of calcium chloride, 0.22-0.28 part of ferrous sulfate, 0.05-0.07 part of manganese sulfate, 38-42 parts of rapeseed oil and 610 parts of sucrose 590-; 17050 parts of 16952 parts of water;
the volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 98-102.
Further, when the beta-1, 3-glucan is prepared, the weight parts of the components are respectively as follows: 20 parts of sodium dihydrogen phosphate, 40 parts of potassium nitrate, 4 parts of magnesium sulfate, 0.14 part of calcium chloride, 0.25 part of ferrous sulfate, 0.06 part of manganese sulfate, 40 parts of rapeseed oil and 600 parts of sucrose; 17000 parts of water;
the volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 100.
Further, the agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows in a culture medium, and the culture medium comprises the following components in parts by weight: 210 portions of water 190-plus, 1.5-2.5 portions of peptone, 0.8-1.2 portions of yeast powder and 1.5-2.5 portions of sodium chloride.
Further, when preparing the beta-1, 3-glucan, the method comprises the following steps:
(1) adding part of water, sodium dihydrogen phosphate, potassium nitrate, magnesium sulfate, calcium chloride, ferrous sulfate, manganese sulfate, rapeseed oil and sucrose into a fermentation tank according to the proportion, dissolving and uniformly stirring to obtain a mixed solution;
(2) adjusting the pH value of the mixed solution obtained in the step (1) to 6.5-7.5, and then carrying out steam sterilization;
(3) cooling the mixed solution subjected to steam sterilization in the step (2) to room temperature;
(4) adding the seed solution of the agrobacterium ZX09 into the mixed solution cooled in the step (3) according to the proportion, adjusting the ventilation flow to 18-22L/min, setting the stirring speed to 250-270rpm and the fermentation temperature to 28-32 ℃, culturing for 58-62h, and obtaining the fermentation liquid after the fermentation is finished;
(5) putting the fermentation liquor obtained in the step (4) into a barrel, adding 95% ethanol to precipitate the fermentation liquor, taking the precipitate, drying by pressure, dissolving the precipitate in the rest water, adding sodium hydroxide and diatomite, uniformly mixing, heating to 88-92 ℃ to obtain a suspension, and repeatedly filtering the suspension by using a plate-and-frame filter press until the solution is clear and transparent; the precipitate and filtrate are retained;
(6) adding 95% ethanol into the filtrate obtained in the step (5) to precipitate the filtrate, and filtering again; keeping the precipitate;
(7) and (4) mixing the precipitates obtained in the step (5) and the step (6), and sequentially performing press drying, drying and crushing to obtain a finished product of the beta-1, 3-glucan.
Further, in the step (2), the steam sterilization is performed for 25-35min at 121 ℃ when preparing the beta-1, 3-glucan.
The structural formula of the beta-1, 3-glucan prepared by the invention is as follows:
the general structural formula is as follows:
poly-3) - β -D-pyran- (l → 3) - [ β -D-pyran- (l → 3) - β -D-pyran-]3- (l → 3) - α -D-pyran- (l → 3) - α -D-pyran- (l → glucose.
The action mechanism of the beta-1, 3-glucan for repairing the skin injury is as follows:
the beta-1, 3-glucan promotes the healing of skin wounds by chemotactic fibroblasts, promoting epidermal regeneration, promoting angiogenesis, and promoting the expression of cytokines TGF-beta 1 (transforming growth factor-beta 1), FGF-2 (fibroblast growth factor-2), EGF (epidermal growth factor) and a cell cycle regulatory protein Cyclin D1.
Based on the technical scheme, the embodiment of the invention can at least produce the following technical effects:
the invention aims to introduce beta-1, 3-glucan into the treatment of repairing skin injury, discloses a new application of the beta-1, 3-glucan, and discloses an application of the beta-1, 3-glucan in preparing medicines and daily chemical products for repairing skin injury; experiments prove that the beta-1, 3-glucan has obvious effects of resisting inflammation, promoting tissue regeneration and promoting wound healing, can show that the beta-1, 3-glucan has a repairing effect on skin, and the beta-1, 3-glucan can be applied to preparation of medicines and daily chemical products for repairing skin injury, thereby laying a certain foundation for development of similar medicines and daily chemical products.
Drawings
In order to illustrate the embodiments or prior art solutions more clearly, the drawings used in the description of the embodiments or prior art will be briefly described below, it is obvious that the drawings in the following description are only some embodiments of the present description, and it is obvious for a person skilled in the art that other drawings can be obtained from these drawings without inventive effort.
FIG. 1 is a graphical representation of the anti-inflammatory effect of beta-1, 3-glucan on zebrafish inflammation;
FIG. 2 shows the anti-inflammatory effect of beta-1, 3-glucan on zebrafish inflammation (neutrophil count);
FIG. 3 is a graph showing the inflammation resolution rate of beta-1, 3-glucan against inflammation in zebrafish;
FIG. 4 is a typical graph of regeneration (arrow marks) of zebrafish tissue after β -1, 3-glucan treatment;
FIG. 5 shows the regeneration length (in pixels) of zebrafish tissue after beta-1, 3-glucan treatment;
FIG. 6 shows the tissue regeneration promoting effect of zebra fish treated with beta-1, 3-glucan;
FIG. 7 is a phenotype plot of pigment recruitment to the wound site following β -1, 3-glucan treatment;
FIG. 8 is a phenotype graph of angiogenesis after treatment of a test article;
FIG. 9 is the sum of the opacity of the wound site of zebrafish after treatment with β -1, 3-glucan;
FIG. 10 shows the wound healing promoting effect of beta-1, 3-glucan on zebrafish after treatment;
FIG. 11 is a graph of the incidence of neoangiogenesis in zebrafish after treatment with β -1, 3-glucan.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the technical solutions of the present invention will be described in detail below. It is to be understood that the described embodiments are merely exemplary of the invention, and not restrictive of the full scope of the invention. All other embodiments, which can be derived by a person skilled in the art from the examples given herein without any inventive step, are within the scope of the present invention.
First, preparation example:
preparation of beta-1, 3-glucan:
example 1:
1.1 component:
20 parts of sodium dihydrogen phosphate, 40 parts of potassium nitrate, 4 parts of magnesium sulfate, 0.14 part of calcium chloride, 0.25 part of ferrous sulfate, 0.06 part of manganese sulfate, 40 parts of rapeseed oil and 600 parts of sucrose; and 17000 parts of water.
The volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 100.
The agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows for 48 hours at the temperature of 30 ℃ in a culture medium, and the culture medium comprises the following components in parts by weight: 200 parts of water, 2 parts of peptone, 1 part of yeast powder and 2 parts of sodium chloride.
1.2: the preparation method comprises the following steps:
the method comprises the following steps:
(1) adding part of water, sodium dihydrogen phosphate, potassium nitrate, magnesium sulfate, calcium chloride, ferrous sulfate, manganese sulfate, rapeseed oil and sucrose into a fermentation tank according to the proportion, dissolving and uniformly stirring to obtain a mixed solution; the adding amount of the water is 90 percent of the total weight of the water;
(2) adjusting the pH value of the mixed solution obtained in the step (1) to 7, and then performing steam sterilization (sterilization at the temperature of 121 ℃ for 30 min);
(3) cooling the mixed solution subjected to steam sterilization in the step (2) to room temperature;
(4) adding the agrobacterium ZX09 seed solution into the mixed solution cooled in the step (3) according to the proportion, then introducing sterile air, adjusting the ventilation flow to 20L/min, setting the stirring rotation speed to be 260rpm and the fermentation temperature to be 30 ℃, culturing for 60h, and obtaining fermentation liquor after the fermentation is finished;
(5) putting the fermentation liquor obtained in the step (4) into a barrel, adding 95% ethanol to precipitate the fermentation liquor, taking the precipitate, pressing and drying the precipitate, dissolving the precipitate in the rest water, adding sodium hydroxide (the adding amount of the sodium hydroxide is 2% of the volume of the existing solution) and diatomite (the adding amount of the diatomite is 0.1% of the volume of the existing solution), uniformly mixing, heating to 90 ℃ to obtain suspension, and repeatedly filtering the suspension by using a plate-and-frame filter press until the solution is clear and transparent; the precipitate and filtrate are retained;
(6) adding 95% ethanol into the filtrate obtained in the step (5) to precipitate the filtrate, and filtering again; keeping the precipitate;
(7) and (4) mixing the precipitates obtained in the step (5) and the step (6), and sequentially performing press drying, drying and crushing to obtain a finished product of the beta-1, 3-glucan.
Example 2:
2.1 component:
25 parts of sodium dihydrogen phosphate, 45 parts of potassium nitrate, 3 parts of magnesium sulfate, 0.1 part of calcium chloride, 0.3 part of ferrous sulfate, 0.08 part of manganese sulfate, 35 parts of rapeseed oil and 620 parts of cane sugar; 169900 parts of water.
The volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 95.
The agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows for 48 hours at the temperature of 30 ℃ in a culture medium, and the culture medium comprises the following components in parts by weight: 195 parts of water, 2.5 parts of peptone, 1.2 parts of yeast powder and 1.2 parts of sodium chloride.
2.2: the preparation method comprises the following steps:
the method comprises the following steps:
(1) adding part of water, sodium dihydrogen phosphate, potassium nitrate, magnesium sulfate, calcium chloride, ferrous sulfate, manganese sulfate, rapeseed oil and sucrose into a fermentation tank according to the proportion, dissolving and uniformly stirring to obtain a mixed solution; the adding amount of the water is 90 percent of the total weight of the water;
(2) adjusting the pH value of the mixed solution obtained in the step (1) to 6.5, and then performing steam sterilization (sterilization at the temperature of 121 ℃ for 25 min);
(3) cooling the mixed solution subjected to steam sterilization in the step (2) to room temperature;
(4) adding the agrobacterium ZX09 seed solution into the mixed solution cooled in the step (3) according to the ratio, introducing sterile air, adjusting the aeration flow to 22L/min, setting the stirring speed to 270rpm and the fermentation temperature to 32 ℃, culturing for 58h, and obtaining fermentation liquor after the fermentation is finished;
(5) putting the fermentation liquor obtained in the step (4) into a barrel, adding 95% ethanol to precipitate the fermentation liquor, taking the precipitate, pressing and drying the precipitate, dissolving the precipitate in the rest water, adding sodium hydroxide (the adding amount of the sodium hydroxide is 2% of the volume of the existing solution) and diatomite (the adding amount of the diatomite is 0.1% of the volume of the existing solution), uniformly mixing, heating to 92 ℃ to obtain suspension, and repeatedly filtering the suspension by using a plate-and-frame filter press until the solution is clear and transparent; the precipitate and filtrate are retained;
(6) adding 95% ethanol into the filtrate obtained in the step (5) to precipitate the filtrate, and filtering again; keeping the precipitate;
(7) and (4) mixing the precipitates obtained in the step (5) and the step (6), and sequentially performing press drying, drying and crushing to obtain a finished product of the beta-1, 3-glucan.
Example 3:
3.1 component:
25 parts of sodium dihydrogen phosphate, 35 parts of potassium nitrate, 5 parts of magnesium sulfate, 0.2 part of calcium chloride, 0.2 part of ferrous sulfate, 0.04 part of manganese sulfate, 45 parts of rapeseed oil and 580 parts of cane sugar; 17100 parts of water.
The volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 105.
The agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows for 48 hours at the temperature of 30 ℃ in a culture medium, and the culture medium comprises the following components in parts by weight: 205 parts of water, 1.5 parts of peptone, 0.8 part of yeast powder and 0.8 part of sodium chloride.
3.2: the preparation method comprises the following steps:
the method comprises the following steps:
(1) adding part of water, sodium dihydrogen phosphate, potassium nitrate, magnesium sulfate, calcium chloride, ferrous sulfate, manganese sulfate, rapeseed oil and sucrose into a fermentation tank according to the proportion, dissolving and uniformly stirring to obtain a mixed solution; the adding amount of the water is 90 percent of the total weight of the water;
(2) adjusting the pH value of the mixed solution obtained in the step (1) to 7.5, and then performing steam sterilization (sterilization is performed for 35min at the temperature of 121 ℃);
(3) cooling the mixed solution subjected to steam sterilization in the step (2) to room temperature;
(4) adding the agrobacterium ZX09 seed solution into the mixed solution cooled in the step (3) according to the proportion, then introducing sterile air, adjusting the aeration flow to 18L/min, setting the stirring rotation speed to be 250rpm and the fermentation temperature to be 28 ℃, culturing for 62h, and obtaining fermentation liquor after the fermentation is finished;
(5) putting the fermentation liquor obtained in the step (4) into a barrel, adding 95% ethanol to precipitate the fermentation liquor, taking the precipitate, pressing and drying the precipitate, dissolving the precipitate in the rest water, adding sodium hydroxide (the adding amount of the sodium hydroxide is 2% of the volume of the existing solution) and diatomite (the adding amount of the diatomite is 0.1% of the volume of the existing solution), uniformly mixing, heating to 88 ℃ to obtain suspension, and repeatedly filtering the suspension by using a plate-and-frame filter press until the solution is clear and transparent; the precipitate and filtrate are retained;
(6) adding 95% ethanol into the filtrate obtained in the step (5) to precipitate the filtrate, and filtering again; keeping the precipitate;
(7) and (4) mixing the precipitates obtained in the step (5) and the step (6), and sequentially performing press drying, drying and crushing to obtain a finished product of the beta-1, 3-glucan.
Example 4:
4.1 component:
22 parts of sodium dihydrogen phosphate, 38 parts of potassium nitrate, 4.5 parts of magnesium sulfate, 0.18 part of calcium chloride, 0.22 part of ferrous sulfate, 0.07 part of manganese sulfate, 38 parts of rapeseed oil and 610 parts of sucrose; 16950 parts of water.
The volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 98.
The agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows for 48 hours at the temperature of 30 ℃ in a culture medium, and the culture medium comprises the following components in parts by weight: 198 parts of water, 2.2 parts of peptone, 1.1 parts of yeast powder and 1.1 parts of sodium chloride.
4.2: the preparation method comprises the following steps: the same as in example 1.
Example 5:
5.1 component:
18 parts of sodium dihydrogen phosphate, 42 parts of potassium nitrate, 3.5 parts of magnesium sulfate, 0.12 part of calcium chloride, 0.28 part of ferrous sulfate, 0.05 part of manganese sulfate, 42 parts of rapeseed oil and 610 parts of sucrose; and 17050 parts of water.
The volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 102.
The agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows for 48 hours at the temperature of 30 ℃ in a culture medium, and the culture medium comprises the following components in parts by weight: 202 parts of water, 1.8 parts of peptone, 0.9 part of yeast powder and 0.9 part of sodium chloride.
5.2: the preparation method comprises the following steps: the same as in example 1.
Second, experimental example:
(I), the water solubility experiment was performed using the beta-1, 3-glucan prepared in examples 1-5, while comparing the water solubility of oat glucan, yeast glucan and lentinan.
The experimental method comprises the following steps: beta-1, 3-glucan prepared in examples 1 to 5 and oat glucan, yeast glucan and lentinan were dissolved in deionized water at room temperature at a weight percentage of 5%, respectively, and sufficiently dissolved by stirring, and the dissolution results were observed to compare the water solubility.
The results of the experiment, as shown in table 1 below:
TABLE 1 Water solubility test results
| Result of dissolution | |
| Example 1 | Clear and transparent solution |
| Example 2 | Clear and transparent solution |
| Example 3 | Clear and transparent solution |
| Example 4 | Clear and transparent solution |
| Example 5 | Clear and transparent solution |
| Oat glucan | Turbidity and incomplete dissolution |
| Yeast glucan | Turbidity and incomplete dissolution |
| Lentinan | The solution is light yellow after dissolution, which indicates that the content of impurities is higher |
As can be seen from Table 1, the β -1, 3-glucan prepared in examples 1-5 of the present invention is significantly superior in water solubility to oat glucan, yeast glucan and lentinan, and has a low impurity content.
(II) experiment Using the beta-1, 3-glucan prepared in example 1
Experimental drugs
Beta-1, 3-glucan, white powder; the mother liquor with concentration of 1mg/mL is prepared by fish culture water at the moment of use, and is prepared at present.
Indomethacin, white powder, lot No. 1108939, manufacturer: shanghai crystal industries Ltd. The resulting mixture was stored in 100% dimethyl sulfoxide (80 mM) at-20 ℃ in the dark.
Glacial acetic acid, colorless liquid, lot number L1712010, manufacturer: aladdin reagent (Shanghai) Co., Ltd. The sodium chloride injection is prepared into 5 percent working solution for use at the moment.
Instruments and reagents
Dissecting microscopes (Szx7, Olympus, Japan); a CCD camera (VertA 1); microinjection apparatus (IM-300, Narishige, Japan); needle puller (PC-10, Narishige, Japan); six-well plates (Nest Biotech, China); electric focusing continuous zoom fluorescence microscope (AZ100, Nikon, Japan); methylcellulose (aladin, China); dimethyl sulfoxide (lot No. BCBN0845V, Sigma, France); copper sulfate pentahydrate (lot number L1923177, Aladdin, China); sodium chloride injection (batch No. D18090505, columbic pharmaceuticals, inc., Guizhou).
1. Experimental study on the anti-inflammatory effect of beta-1, 3-glucan.
1.1 Experimental animals
Transgenic neutrophil fluorescent zebrafish, in a natural paired mating breeding mode. There were 390 tails per experimental group, 30 tails per experimental group, and 3 days after fertilization for anti-inflammatory effect evaluation.
Raising the fish in water for fish culture at 28 ℃ (water quality: 200mg of instant sea salt is added into per 1L of reverse osmosis water, the conductivity is 480-510 mu S/cm, the pH is 6.9-7.2, and the hardness is 53.7-71.6 mg/L CaCO3) The license number for experimental animals is as follows: SYXK (Zhe) 2012-0171. The feeding management meets the requirements of international AAALAC certification.
1.2 Experimental concentration groups
1.2.1 determination of the maximum tolerated concentration of beta-1, 3-Glucan (MTC)
Experiment 1 group Normal control group
Experiment 2 model control group
Experiment 3 group beta-1, 3-Glucan 62.5. mu.g/mL
Experiment 4 group beta-1, 3-Glucan 125. mu.g/mL
Experiment 6 group beta-1, 3-Glucan 500. mu.g/mL
Experiment 7 group of beta-1, 3-Glucan 1000. mu.g/mL
1.2.2 evaluation of the anti-inflammatory action of beta-1, 3-Glucan
Experiment 1 group Normal control group
Experiment 2 model control group
Experiment 3 group positive control drug indomethacin 80. mu.M
Experiment 4 group of beta-1, 3-Glucan 111. mu.g/mL
Experiment 6 group 1000. mu.g/mL of beta-1, 3-glucan
1.3 model making
Treating the transgenic neutrophilic granulocyte fluorescent zebra fish by 10 mu M copper sulfate in a water-soluble mode for induction for 2 hours, and establishing a zebra fish inflammation model.
1.4 basis for determination of concentration
According to the concentration results, the anti-inflammatory effect of the beta-1, 3-glucan is evaluated to be 1000 mug/mL of MTC. The anti-inflammatory effect evaluation concentrations were set to 111. mu.g/mL, 333. mu.g/mL, and 1000. mu.g/mL according to the project recommendation.
1.5 Experimental methods
1.5.1 determination of the maximum tolerated concentration of beta-1, 3-Glucan (MTC)
Randomly selecting 3dpf transgenic neutrophilic granulocyte fluorescent zebra fish in a six-hole plate, wherein 30 fish in each hole and a copper sulfate-induced zebra fish inflammation model are dissolved in water respectively to give concentrations of 62.5 mu g/mL, 125 mu g/mL, 250 mu g/mL, 500 mu g/mL and 1000 mu g/mL of beta-1, 3-glucan; 3mL of liquid medicine is put in each hole, and a normal control group and a model control group are simultaneously arranged; after incubation for 3h in an incubator at 28 ℃, counting the death number and toxicity of the zebra fish of each experimental group, and determining the MTC of the test sample.
1.5.2 evaluation of the anti-inflammatory action of beta-1, 3-Glucan
Randomly selecting 3dpf transgenic neutrophilic granulocyte fluorescent zebra fish in a six-hole plate, wherein 30 fish in each hole are subjected to copper sulfate induced zebra fish inflammation model, and respectively carrying out water dissolution on 111 mu g/mL, 333 mu g/mL and 1000 mu g/mL concentrations of beta-1, 3-glucan; the concentration of indometacin serving as a positive control drug is 80 mu M; setting a normal control group and a model control group at the same time; after incubation in an incubator at 28 ℃ for 3h, randomly taking 10 zebra fish from each group, observing under a fluorescence microscope, photographing and storing pictures; the image analysis is carried out by Nikon NIS-Elements D3.10 advanced image processing software, the number (N) of the inflammatory neutrophils of the zebra fish is calculated, the quantitative analysis is carried out, and the inflammatory regression rate of the test sample is calculated according to the following formula:
statistical analysis using analysis of variance and Dunnett's T-test, p <0.05 indicated significant differences; representative experimental profiles are provided.
1.6, results of the experiment
1.6.1 maximum tolerated concentration of beta-1, 3-Glucan (MTC)
No zebrafish death and significant toxic phenotype was seen in 30 tail zebrafish at 62.5. mu.g/mL, 125. mu.g/mL, 250. mu.g/mL, 500. mu.g/mL and 1000. mu.g/mL (maximum solubility) concentrations of beta-1, 3-glucan. Thus, the anti-inflammatory effect of β -1, 3-glucan was evaluated at 1000 μ g/mL MTC. See table 2 for details.
Table 2 statistics of zebrafish mortality at assay concentration of β -1, 3-glucan (n ═ 30)
1.6.2 anti-inflammatory action of beta-1, 3-Glucan
Compared with the normal control group (2.7), the number (20.6) of the neutrophils at the inflammation part of the model control group is p <0.001, which indicates that the model is successfully established; compared with the model control group, the count of the neutrophils in the indometacin group (12.5) is less than 0.001, the inflammation resolution rate is 38%, and the indometacin has an anti-inflammatory effect.
The numbers of neutrophils at the inflammation parts of the concentrations of 111 mu g/mL, 333 mu g/mL and 1000 mu g/mL of beta-1, 3-glucan are respectively 20.3, 16.0 and 12.3, and compared with a model control group, the numbers of p are respectively greater than 0.05& p <0.05& p <0.001, and the inflammation resolution rates are respectively 5%, 24% and 43%, which indicates that the beta-1, 3-glucan has obvious anti-inflammatory effect on the inflammation of the zebra fish induced by the copper sulfate under the experimental concentration condition and presents a dose-dependent trend. See table 3, fig. 1, fig. 2 and fig. 3 for details.
FIG. 1 is a graphical representation of the anti-inflammatory effect of beta-1, 3-glucan on zebrafish inflammation, with the arrows in FIG. 1 indicating neutrophils at the site of inflammation;
figure 2 is an anti-inflammatory effect of β -1, 3-glucan on zebrafish inflammation (neutrophil count), p <0.05, p <0.001 compared to model control;
fig. 3 shows the inflammation resolution rate of β -1, 3-glucan on zebrafish inflammation, p <0.05, p <0.001, compared to the model control group.
Table 3 quantification of the anti-inflammatory effect of β -1, 3-glucan on zebrafish inflammation (n ═ 10)
P <0.05, p <0.001, compared to model control group
2. Experimental study on the tissue regeneration effect of beta-1, 3-glucan.
2.1 Experimental animals
Wild type AB strain zebrafish, in a natural mated mating breeding mode. Total 330, 30 in each experimental group and 3 days after fertilization, were used for tissue regeneration evaluation.
Raising the fish in water for fish culture at 28 ℃ (water quality: 200mg of instant sea salt is added into per 1L of reverse osmosis water, the conductivity is 480-510 mu S/cm, the pH is 6.9-7.2, and the hardness is 53.7-71.6 mg/L CaCO3) The license number for experimental animals is as follows: SYXK (Zhe) 2012-0171. The feeding management meets the requirements of international AAALAC certification.
2.2, concentration group
2.2.1 determination of the Maximum Tolerated Concentration (MTC) of beta-1, 3-glucan
Experiment 1 group Normal control group
Experiment 2 group beta-1, 3-Glucan 62.5. mu.g/mL
Experiment 3 group beta-1, 3-Glucan 125. mu.g/mL
Experiment 4 group beta-1, 3-Glucan 250. mu.g/mL
Experiment 6 group 1000. mu.g/mL of beta-1, 3-glucan
2.2.2 evaluation of tissue regeneration Effect of beta-1, 3-glucan
Experiment 1 group Normal control group
Experiment 2 model control group
Experiment 3 group beta-1, 3-Glucan 111. mu.g/mL
Experiment 4 group beta-1, 3-Glucan 333. mu.g/mL
2.3 model making
And cutting the tail fin of the zebra fish to establish a zebra fish tissue regeneration model.
2.4 basis for determination of concentration
According to the concentration results, the anti-inflammatory effect of the beta-1, 3-glucan is evaluated to be 1000 mug/mL of MTC. According to the requirements of the project recommendation, the tissue regeneration promoting effect evaluation concentrations were set to 111. mu.g/mL, 333. mu.g/mL and 1000. mu.g/mL.
2.5 Experimental methods
2.5.1 determination of the Maximum Tolerated Concentration (MTC) of beta-1, 3-glucan
Randomly selecting 3dpf wild type AB strain zebra fish in a six-hole plate, dissolving 30 fish in water for beta-1, 3-glucan at 62.5 mu g/mL, 125 mu g/mL, 250 mu g/mL, 500 mu g/mL and 1000 mu g/mL respectively; 3mL of liquid medicine is added into each hole, and a normal control group is arranged at the same time; after incubation for 3 days in an incubator at 28 ℃, the death number and toxicity of the zebra fish of each experimental group are counted, and the MTC of the test sample is determined.
2.5.2 evaluation of tissue regeneration Effect of beta-1, 3-glucan
Randomly selecting 3dpf wild AB strain zebra fish, and establishing a zebra fish tissue regeneration promoting model by a method of cutting tail fins by operation. Water-soluble administration of beta-1, 3-glucan at 111. mu.g/mL, 333. mu.g/mL and 1000. mu.g/mL, respectively; the normal control group and the model control group were set at the same time. After incubation in an incubator at 28 ℃ for 3 days, randomly selecting 10 zebra fishes from each group, photographing under an anatomical microscope, storing pictures, analyzing and counting the tissue regeneration length of the zebra fishes, and expressing the statistical processing result by mean plus or minus SE; the calculation formula of the test product on the tissue regeneration promotion effect is as follows:
statistical analysis using analysis of variance and Dunnett's T-test, p <0.05 indicated significant differences.
2.6 results of the experiment
2.6.1 maximum tolerated concentration of beta-1, 3-Glucan (MTC)
No zebrafish death and significant toxic phenotype was seen in 30 tail zebrafish at 62.5. mu.g/mL, 125. mu.g/mL, 250. mu.g/mL, 500. mu.g/mL and 1000. mu.g/mL (maximum solubility) concentrations of beta-1, 3-glucan. Thus, the anti-inflammatory effect of β -1, 3-glucan was evaluated at 1000 μ g/mL MTC. See table 4 for details.
Table 4 statistics of zebrafish mortality at assay concentration of β -1, 3-glucan (n ═ 30)
2.6.2 evaluation of tissue regeneration Effect of beta-1, 3-glucan
Comparing the length of tail fin of zebra fish in model control group (198 pixels) with that in normal control group (352 pixels), p is less than 0.001, which indicates that the model is successfully established.
The tail fin lengths of the concentrations of beta-1, 3-glucan 111. mu.g/mL, 333. mu.g/mL and 1000. mu.g/mL were 219, 268 and 273 pixels, respectively, and compared to the model control group, p >0.05& p <0.001& p <0.001, respectively, and the tissue regeneration promoting effects were 11%, 35% and 38%. The experimental concentration condition indicates that the beta-1, 3-glucan has the effect of promoting regeneration of zebra fish tissues. See table 5, fig. 4, fig. 5 and fig. 6 for details.
FIG. 4 is a typical graph of regeneration (arrow marks) of zebrafish tissue after β -1, 3-glucan treatment;
figure 5 shows the length of regeneration (in pixels) of zebrafish tissue after β -1, 3-glucan treatment compared to model controls, { circumflex over (p) } 0.001;
figure 6 shows the regeneration promoting effect of zebrafish tissue after treatment with β -1, 3-glucan, p <0.001 compared to model control.
Table 5 length analysis of zebra fish tail fin after β -1, 3-glucan treatment (n ═ 10)
P <0.001 in comparison to model control group
3. Experimental study of the effect of β -1, 3-glucan on wound healing.
3.1 Experimental animals
Transgenic vascular fluorescent zebrafish Fli-1 lines were bred in natural pairwise mating. The total number of 150, 30 in each experimental group and the age 2 days after fertilization were used for evaluation of wound healing promotion effect.
Raising the fish in water for fish culture at 28 ℃ (water quality: 200mg of instant sea salt is added into per 1L of reverse osmosis water, the conductivity is 480-510 mu S/cm, the pH is 6.9-7.2, and the hardness is 53.7-71.6 mg/L CaCO3) The license number for experimental animals is as follows: SYXK (Zhe) 2012-0171. The feeding management meets the requirements of international AAALAC certification.
3.2 concentration group
Experiment 1 group Normal control group
Experiment 2 model control group
Experiment 3 group beta-1, 3-Glucan 111. mu.g/mL
Experiment 4 group beta-1, 3-Glucan 333. mu.g/mL
3.3 model making
Glacial acetic acid is used for treating normal zebra fish in an injection administration mode, and a wound healing model is established.
3.4 basis for determination of concentration
The concentration of the beta-1, 3-glucan MTC obtained from the experiment two was found to be 1000. mu.g/mL. According to the requirements of the project recommendation, the concentrations for evaluation of wound-healing-promoting effects were set to 111. mu.g/mL, 333. mu.g/mL, and 1000. mu.g/mL.
3.5 Experimental methods
Selecting a 2dpf transgenic vascular fluorescent zebra fish Fli-1 strain, injecting glacial acetic acid into the trunk (the intersection of a spinal chord and a cloaca hole) of the zebra fish to establish a zebra fish wound healing model, and selecting the zebra fish with consistent wound injury degree to randomly group. The beta-1, 3-glucan was administered to treat at concentrations of 111. mu.g/mL, 333. mu.g/mL and 1000. mu.g/mL, respectively, while a normal control group (zebrafish treated with water for fish farming) and a model control group were set, each group (well) treated with 30 zebrafish, and each group (well) had a volume of 3 mL. After incubation in an incubator at 28 ℃ for 2 days, randomly selecting 10 zebra fishes in each group, collecting pictures under a fluorescence microscope, carrying out image analysis by using image processing software, calculating (1) the angiogenesis rate of a wound part, (2) the total opacity (S) of pigments of the wound part, and expressing a statistical processing result by mean +/-SE; the calculation formula of the test article for promoting wound healing is as follows:
statistical analysis using analysis of variance and Dunnett's T-test, p <0.05 indicated significant differences; representative experimental profiles are provided.
3.6 results of the experiment
The total opacity of the wound site of the zebra fish in the model control group is 118112 pixels, and p is less than 0.001 compared with that in the normal control group (73542 pixels); the model control group has obvious vascular injury during modeling, and after 2 days, 50% of new blood vessels appear in the model control group, which indicates that the establishment of the zebra fish wound healing model is successful.
At the concentrations of 111 mu g/mL, 333 mu g/mL and 1000 mu g/mL of beta-1, 3-glucan, the total opacity of the wound site of the zebra fish is 103362, 101383 and 91772 pixels respectively, and compared with a model control group (118112 pixels), p is less than 0.05& p is less than 0.01& p is less than 0.001, and the promotion effect on the wound healing of the zebra fish is 12%, 14% and 22% respectively; the angiogenesis rates of the wound parts of the zebra fish are respectively 60%, 65% and 80%, and compared with a model control group (50%), the average p is more than 0.05, which shows that the concentrations of 111 mug/mL, 333 mug/mL and 1000 mug/mL of beta-1, 3-glucan have obvious promotion effect on the wound healing of the zebra fish.
See table 6, fig. 7, fig. 8, fig. 9, fig. 10 and fig. 11 for details.
FIG. 7 is a phenotype plot of pigment recruitment to the wound site following β -1, 3-glucan treatment;
FIG. 8 is a diagram showing the appearance of blood vessels newly formed after the treatment of the test sample, and the white arrows indicate the new blood vessels;
figure 9 is the sum of the opacity at the wound site of zebrafish after β -1, 3-glucan treatment, p <0.05, p <0.01, p <0.001 compared to model control;
figure 10 shows the wound healing promotion effect on zebrafish after β -1, 3-glucan treatment, p <0.05, p <0.01, p < 0.001;
FIG. 11 is a graph of the incidence of neoangiogenesis in zebrafish after treatment with β -1, 3-glucan.
TABLE 6 promotion of wound healing in Zebra fish by β -1, 3-glucan (n ═ 10)
In conclusion, under the concentration condition of the experiment, the beta-1, 3-glucan prepared in the example 1 has obvious effects of resisting inflammation, promoting tissue regeneration and promoting wound healing, and the beta-1, 3-glucan has a repairing effect on skin injury.
(III), the application of example 2-5 preparation of beta-1, 3-glucan experiment, and the preparation of example 1 preparation of beta-1, 3-glucan experiment of the same experimental results.
The above description is only for the specific embodiments of the present invention, but the scope of the present invention is not limited thereto, and any person skilled in the art can easily conceive of the changes or substitutions within the technical scope of the present invention, and all the changes or substitutions should be covered within the scope of the present invention.
Claims (10)
1. Application of beta-1, 3-glucan in preparing medicines and daily chemical products for repairing skin injury.
2. Application of beta-1, 3-glucan in preparing anti-inflammatory drugs and daily chemical products for skin.
3. Application of beta-1, 3-glucan in preparing medicines and daily chemical products for promoting skin tissue regeneration.
4. Application of beta-1, 3-glucan in preparing medicines and daily chemical products for promoting skin wound healing.
5. Use according to any one of claims 1 to 4, characterized in that: the beta-1, 3-glucan can be used alone or in combination with other drugs.
6. Use according to any one of claims 1 to 4, characterized in that: the preparation of the beta-1, 3-glucan comprises the following components in parts by weight: 15-25 parts of sodium dihydrogen phosphate, 35-45 parts of potassium nitrate, 3-5 parts of magnesium sulfate, 0.1-0.2 part of calcium chloride, 0.2-0.3 part of ferrous sulfate, 0.04-0.08 part of manganese sulfate, 35-45 parts of rapeseed oil and 620 parts of cane sugar 580-doped materials; water 169900 and 17100 shares;
the preparation also comprises an agrobacterium ZX09 seed solution, and the volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 95-105.
7. Use according to claim 6, characterized in that: when the beta-1, 3-glucan is prepared, the weight parts of the components are respectively as follows: 18-22 parts of sodium dihydrogen phosphate, 38-42 parts of potassium nitrate, 3.5-4.5 parts of magnesium sulfate, 0.12-0.18 part of calcium chloride, 0.22-0.28 part of ferrous sulfate, 0.05-0.07 part of manganese sulfate, 38-42 parts of rapeseed oil and 610 parts of sucrose 590-; 17050 parts of 16952 parts of water;
the volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 98-102.
8. Use according to claim 7, characterized in that: when the beta-1, 3-glucan is prepared, the weight parts of the components are respectively as follows: 20 parts of sodium dihydrogen phosphate, 40 parts of potassium nitrate, 4 parts of magnesium sulfate, 0.14 part of calcium chloride, 0.25 part of ferrous sulfate, 0.06 part of manganese sulfate, 40 parts of rapeseed oil and 600 parts of sucrose; 17000 parts of water;
the volume ratio of the agrobacterium ZX09 seed solution to the total volume of the components is 1: 100.
9. Use according to claim 8, characterized in that: the agrobacterium ZX09 seed solution is a mixture formed after agrobacterium ZX09 grows in a culture medium, and the culture medium comprises the following components in parts by weight: 210 portions of water 190-plus, 1.5-2.5 portions of peptone, 0.8-1.2 portions of yeast powder and 1.5-2.5 portions of sodium chloride.
10. Use according to claim 9, characterized in that: the preparation of the beta-1, 3-glucan comprises the following steps:
(1) adding part of water, sodium dihydrogen phosphate, potassium nitrate, magnesium sulfate, calcium chloride, ferrous sulfate, manganese sulfate, rapeseed oil and sucrose into a fermentation tank according to the proportion, dissolving and uniformly stirring to obtain a mixed solution;
(2) adjusting the pH value of the mixed solution obtained in the step (1) to 6.5-7.5, and then carrying out steam sterilization;
(3) cooling the mixed solution subjected to steam sterilization in the step (2) to room temperature;
(4) adding the seed solution of the agrobacterium ZX09 into the mixed solution cooled in the step (3) according to the proportion, adjusting the ventilation flow to 18-22L/min, setting the stirring speed to 250-270rpm and the fermentation temperature to 28-32 ℃, culturing for 58-62h, and obtaining the fermentation liquid after the fermentation is finished;
(5) putting the fermentation liquor obtained in the step (4) into a barrel, adding 95% ethanol to precipitate the fermentation liquor, taking the precipitate, drying by pressure, dissolving the precipitate in the rest water, adding sodium hydroxide and diatomite, uniformly mixing, heating to 88-92 ℃ to obtain a suspension, and repeatedly filtering the suspension by using a plate-and-frame filter press until the solution is clear and transparent; the precipitate and filtrate are retained;
(6) adding 95% ethanol into the filtrate obtained in the step (5) to precipitate the filtrate, and filtering again; keeping the precipitate;
(7) and (4) mixing the precipitates obtained in the step (5) and the step (6), and sequentially performing press drying, drying and crushing to obtain a finished product of the beta-1, 3-glucan.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010759735.8A CN111773239A (en) | 2020-07-31 | 2020-07-31 | Application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202010759735.8A CN111773239A (en) | 2020-07-31 | 2020-07-31 | Application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN111773239A true CN111773239A (en) | 2020-10-16 |
Family
ID=72766390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202010759735.8A Pending CN111773239A (en) | 2020-07-31 | 2020-07-31 | Application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN111773239A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112826977A (en) * | 2020-12-31 | 2021-05-25 | 山东纳美德生物科技有限公司 | Liquid dressing, skin external composition, preparation method and application thereof |
| US11384160B1 (en) | 2021-07-30 | 2022-07-12 | Tissue repair ltd | Method of making a beta glucan compound |
| CN115337215A (en) * | 2022-07-25 | 2022-11-15 | 天津天隆江大生物科技有限公司 | Product rich in water-soluble beta-1, 3 glucan and preparation method thereof |
| CN115400142A (en) * | 2022-08-25 | 2022-11-29 | 四川合泰新光生物科技有限公司 | Application of beta-1, 3/alpha-1, 3-glucan in preparation of product for regulating skin microecology |
| US11572420B1 (en) | 2021-07-30 | 2023-02-07 | Tissue repair ltd | Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN117137938A (en) * | 2023-09-08 | 2023-12-01 | 广州小蛮腰医疗器械有限公司 | Pharmaceutical composition for repairing vaginal injury |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233469A (en) * | 1998-04-28 | 1999-11-03 | 王京杭 | Tissue restoration accelerator |
| CN101935623A (en) * | 2010-04-14 | 2011-01-05 | 南京理工大学 | Agrobacterium ZX09, water-soluble beta-glucan prepared from Agrobacterium ZX09 and preparation method thereof and application on reducing blood sugar |
| CN103735566A (en) * | 2013-12-26 | 2014-04-23 | 南京理工大学 | Application of soracan gum in inhibiting skin injury of ultraviolet ray |
| CN104116756A (en) * | 2014-08-06 | 2014-10-29 | 南京理工大学 | Application of soracan gum for preparing medicine for promoting skin wound healing |
| CN109593142A (en) * | 2018-12-21 | 2019-04-09 | 江南大学 | A method of reducing β -1,3 glucan, gel strength is lost in the drying process |
| CN110241150A (en) * | 2019-06-25 | 2019-09-17 | 南京曜动节能环保科技有限公司 | The amplification fermentation process of β -1,3- glucan |
| CN110551786A (en) * | 2019-09-12 | 2019-12-10 | 浙江海正药业股份有限公司 | Fermentation medium for increasing yield of A40926B 0 and method thereof |
| CN110893149A (en) * | 2019-12-30 | 2020-03-20 | 盛芮医疗科技(杭州)有限公司 | Composition added with natural antibacterial repair components, preparation method and application thereof |
-
2020
- 2020-07-31 CN CN202010759735.8A patent/CN111773239A/en active Pending
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1233469A (en) * | 1998-04-28 | 1999-11-03 | 王京杭 | Tissue restoration accelerator |
| CN101935623A (en) * | 2010-04-14 | 2011-01-05 | 南京理工大学 | Agrobacterium ZX09, water-soluble beta-glucan prepared from Agrobacterium ZX09 and preparation method thereof and application on reducing blood sugar |
| CN103735566A (en) * | 2013-12-26 | 2014-04-23 | 南京理工大学 | Application of soracan gum in inhibiting skin injury of ultraviolet ray |
| CN104116756A (en) * | 2014-08-06 | 2014-10-29 | 南京理工大学 | Application of soracan gum for preparing medicine for promoting skin wound healing |
| CN109593142A (en) * | 2018-12-21 | 2019-04-09 | 江南大学 | A method of reducing β -1,3 glucan, gel strength is lost in the drying process |
| CN110241150A (en) * | 2019-06-25 | 2019-09-17 | 南京曜动节能环保科技有限公司 | The amplification fermentation process of β -1,3- glucan |
| CN110551786A (en) * | 2019-09-12 | 2019-12-10 | 浙江海正药业股份有限公司 | Fermentation medium for increasing yield of A40926B 0 and method thereof |
| CN110893149A (en) * | 2019-12-30 | 2020-03-20 | 盛芮医疗科技(杭州)有限公司 | Composition added with natural antibacterial repair components, preparation method and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| AIHUI XIU等: "The chemical and digestive properties of a soluble glucan from Agrobacterium sp. ZX09", 《CARBOHYDRATE POLYMERS》 * |
| 余晓红: "索拉胶对皮肤的保护作用研究", 《中国优秀博硕士学位论文全文数据库（硕士） 医药卫生科技辑》 * |
| 张建法等: "索拉胶(β-1,3-葡聚糖)技术开发与应用研究", 《科技成果》 * |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112826977A (en) * | 2020-12-31 | 2021-05-25 | 山东纳美德生物科技有限公司 | Liquid dressing, skin external composition, preparation method and application thereof |
| US11384160B1 (en) | 2021-07-30 | 2022-07-12 | Tissue repair ltd | Method of making a beta glucan compound |
| US11572420B1 (en) | 2021-07-30 | 2023-02-07 | Tissue repair ltd | Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof |
| US11912795B2 (en) | 2021-07-30 | 2024-02-27 | Tissue repair ltd | Isolated biological polysaccharide compound, methods of use and methods of manufacture thereof |
| CN115337215A (en) * | 2022-07-25 | 2022-11-15 | 天津天隆江大生物科技有限公司 | Product rich in water-soluble beta-1, 3 glucan and preparation method thereof |
| CN115337215B (en) * | 2022-07-25 | 2024-02-23 | 天津天隆江大生物科技有限公司 | Product rich in water-soluble beta-1, 3 glucan and preparation method thereof |
| CN115400142A (en) * | 2022-08-25 | 2022-11-29 | 四川合泰新光生物科技有限公司 | Application of beta-1, 3/alpha-1, 3-glucan in preparation of product for regulating skin microecology |
| CN115400142B (en) * | 2022-08-25 | 2023-09-19 | 四川合泰新光生物科技有限公司 | Application of beta-1, 3/alpha-1, 3-glucan in preparation of skin micro-ecological regulating product |
| CN116549494A (en) * | 2023-07-07 | 2023-08-08 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN116549494B (en) * | 2023-07-07 | 2023-09-01 | 四川合泰新光生物科技有限公司 | Beta-1, 3/alpha-1, 3-glucan compound composition with bowel relaxing function and preparation method and application thereof |
| CN117137938A (en) * | 2023-09-08 | 2023-12-01 | 广州小蛮腰医疗器械有限公司 | Pharmaceutical composition for repairing vaginal injury |
| CN117137938B (en) * | 2023-09-08 | 2024-04-05 | 广州小蛮腰医疗器械有限公司 | Pharmaceutical composition for repairing vaginal injury |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN111773239A (en) | Application of beta-1, 3-glucan in preparation of medicines and daily chemical products for repairing skin injuries | |
| DE69630455T2 (en) | PRODUCTION OF BETA -GLUKAN-MANNAN PREPARATIONS BY AUTOLYSIS OF CELLS UNDER SPECIFIC pH, TEMPERATURE AND TIME CONDITIONS | |
| JP5517215B2 (en) | Fermentation and culture method, plant fermented extract, plant fermented extract powder and blended plant fermented extract | |
| DE69107046T2 (en) | Food and drink containing algin. | |
| EA018687B1 (en) | Fraction of glycolipids of fermented extrats of biological food material and pharmaceutical composition comprising said fraction | |
| CN111778300A (en) | Beta-1, 3-glucan and preparation method and application thereof | |
| CN1608487A (en) | Feed additive containing chitin oligose and its prepn and use | |
| CN105193709B (en) | A kind of enrofloxacin injection and preparation method thereof | |
| KR100585500B1 (en) | Feed additives and feed containing thesame for domestic eel(anguilla japonica) | |
| CN115380993B (en) | Clathrate compound containing baohuoside I, composition, preparation method and application thereof | |
| Dzhabrailova et al. | Characterization of Physico-Chemical Parameters and Toxicological Properties of Neocytin | |
| CN111617099B (en) | Nonreactive high-cell affinity colitis restoration agent and application method thereof | |
| CN114425036A (en) | Basic tylosin injection and preparation method thereof | |
| CH646059A5 (en) | ANTIBIOTIC COMPOSITIONS CONTAINING A MACROLIDE AND AN AMINOHETEROSIDE. | |
| CN108451903B (en) | A kind of Betagen Solution and preparation method thereof | |
| EP0904701B1 (en) | Inactivated micro-organisms containing minerals, process for their preparation, and their use in food, veterinary and pharmaceutical compositions | |
| CN109498701A (en) | A kind of Chinese medicine composition and its preparation method and application for preventing and treating goose paramyxovirus | |
| KR19990015681A (en) | Antibiotic feed of fish farming | |
| RU2402207C1 (en) | Method for enhancement of adaptation capabilities of cows | |
| CN1559258A (en) | Use chitin as additive of health-care nutritive forage for fish | |
| DE10111165A1 (en) | Use of hyaluronic acid uronides for the treatment of inflammatory processes | |
| RU2769508C2 (en) | Method for producing combined preparation of animal placenta and phyto-raw material | |
| CN103750330B (en) | Oral composition comprising bovine bone marrow powder and preparation method of oral composition | |
| RU2663463C1 (en) | Method for increasing effectiveness of application of nutrient stimulants in fattening of young cattle | |
| CN116712470A (en) | Pharmaceutical composition for preventing and treating fowl leukocrown disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201016 |